Pharmaceuticals

Global competitive edge due to integrated and efficient manufacturing operations

We believe our large-scale capacity manufacturing sites in India provide us with competitive advantages in terms of economies of scale and operating costs as compared to many of our global competitors. In addition, by the virtue of our integrated operations, we enjoy competitive advantages in the form of cost efficiencies by producing across the value chain, thereby reducing our dependence on third parties for supply of starting materials which helps to insulate us from significant volatility in raw materials prices. The APIs from our manufacturing facility is used for the Solid Dosage Formulations business. Such integration between our Solid Dosage Formulations and APIs business lines allows us to continuously improve our cost of production. Additionally, our radiopharmaceutical products are distributed through more than 45 radiopharmacies. We operate our plants in accordance with cGMP and/or other applicable requirements. We currently operate four US FDA-approved manufacturing facilities in North America and two US FDA-approved manufacturing facilities in India.